| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 27 May 2026 | 18 May 2026 |
| Employees Stock Option Plan & Audited Results & Final Dividend Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve 1. Audited financial results of the Company for the quarter and financial year ended 31.03.2026. 2. Audited standalone and consolidated accounts of the Company together with auditors report, for the F.Y ended 31.03.2026. 3. To recommend dividend if any, for the F.Y 2025.26. 4. To grant stock options to the employees of the Company under Bal Pharma Ltd- Employee Stock Option Plan 2025 Board of Directors of the Company has met today and transacted following business, 1. Approved audited financial results of the Company for the quarter and financial year ended 31.03.2026. 2.Recommend dividend of Rs1.20 per equity share of Rs.10 each i.e 12% 3.Appointed Cost Auditors and Internal auditors for the financial year 2026.27. 4. Approved grant of 5,00,000 stock options to the employees of the company under Bal Pharma Ltd-Employee Stock Option Plan-2025 5.Approved preferential issue of 10,00,000 warrants to the promoters. 6. Take shareholders approval for preferential issue through postal ballot. 7.Approved appointment of Mr.Shreepada M.L (M # A66681) as Company Secretary and compliance officer of the company. (As Per BSE Announcement Dated on:27.05.2026) | ||
| Board Meeting | 11 Feb 2026 | 3 Feb 2026 |
| Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve Unaudited standalone and consolidated financial results of the Company for the quarter ended 31.12.2025. Unaudited standalone and consolidated financial results for the quarter ended 31.12.2025. (As Per BSE Announcement Dated on 11.02.2026) | ||
| Board Meeting | 12 Nov 2025 | 4 Nov 2025 |
| Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve standalone and consolidated financial results of the Company for the quarter and half year ended 30.09.2025. Board of Directors of the Company has inter alia 1. Approved the unaudited standalone and consolidate financial results for the quarter ended 30.09.2025. 2. Appointed Dr.B.Mukesh ( DIN # 11295580)as additional Director of the Company. (As Per BSE Announcement Dated on 12.11.2025) | ||
| Board Meeting | 11 Aug 2025 | 29 Jul 2025 |
| Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2025 inter alia to consider and approve 1. Unaudited financial results for the quarter ended 30.06.2025. 2.Convene 38th Annual General Meeting of the Company. 3.To Fix Book Closure dates. 4. Employee Stock Option Plan -2025 5.Merger of Lifezen healthcare Pvt Ltd (Subsidiary) with Bal Pharma Ltd (Holding Company) Board of Directors of the Company has met today and inter alia transacted the following business, 1. Approved the unaudited financial results ( standalone and consolidated ) for the quarter ended 30.06.2025. 2. Convened 38th Annual General meeting of the company on 25th September 2025 at 11.30 am through AV means. 3. Decided to close the register of members from 19.09.2025 to 25.09.2025 ( both days inclusive ) 4. Approved the ESOP -2025 plan, subject to the approval of shareholders. 5. e-Voting dates from 22.09.2025 to 24.09.2025, for the ensuing Annual General Meeting. (As per BSE Announcement Dated on 11/08/2025) Clarification on the outcome of the board meeting held on 11.08.2025. (As Per BSE Announcement Dated on 07.11.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
